Fig 6 - uploaded by Gregory Osterhaus
Content may be subject to copyright.
A model depicting a structural and functional coupling between GABA synthesis and vesicular GABA transport into SV. GAD 65 is anchored to SVs fi rst through forming a protein complex with the chaperone protein, HSC70, followed by association of HSC70 ⅐ GAD 65 complex to CSP, VGAT, and CaMKII on SVs. The sequence of events leading from neuronal stimulation to activation of GAD 65 and packaging of GABA into SVs is discussed in the text. 

A model depicting a structural and functional coupling between GABA synthesis and vesicular GABA transport into SV. GAD 65 is anchored to SVs fi rst through forming a protein complex with the chaperone protein, HSC70, followed by association of HSC70 ⅐ GAD 65 complex to CSP, VGAT, and CaMKII on SVs. The sequence of events leading from neuronal stimulation to activation of GAD 65 and packaging of GABA into SVs is discussed in the text. 

Source publication
Article
Full-text available
l-Glutamic acid decarboxylase (GAD) exists as both membrane-associated and soluble forms in the mammalian brain. Here, we propose that there is a functional and structural coupling between the synthesis of gamma-aminobutyric acid (GABA) by membrane-associated GAD and its packaging into synaptic vesicles (SVs) by vesicular GABA transporter (VGAT). T...

Context in source publication

Context 1
... These two isoforms, through formation of a homodimer or heterodimer, are found in the membrane- associated as well as the soluble extracts and are responsible for the formation of the major inhibitory neurotransmitter GABA (2). Previously, we have shown that SGAD, presumably GAD 67 , is activated by protein dephosphorylation through the Ca 2 ϩ - dependent phosphatase, calcineurin, and is inhibited by phos- phorylation through protein kinase A (23). Conversely, MGAD, presumably GAD 65 , is activated by protein phosphorylation, which is catalyzed by an unidentified membrane-associated kinase (7). Site-directed mutagenesis studies have also shown that several serine residues at the N terminus of MGAD are involved in protein phosphorylation (14). Furthermore, our results indicate that the ATP activation of MGAD activity depends on the integrity of the electrochemical gradient of the SVs (7). This ATP-mediated activation is abolished under conditions that disrupt the vesicular proton gradient, such as in the presence of V-type ATPase inhibitor, protonophore, or ionophore uncouplers (7). It has been well established that GABA uptake into SVs by VGAT depends on the integrity of electrochemical proton gradients (e.g., ⌬ pH and ⌬ ␺ ) of SVs (24). Newly synthesized neurotransmitters were found to be prefer- entially released upon stimulation (25, 26). Furthermore, Angel et al. (26) reported that in a reconstituted system GABA taken up into SVs is derived from newly synthesized GABA. The same authors further postulated that the same molecule, namely GAD, is responsible for both GABA synthesis and transport into SVs. Although this is an intriguing hypothesis, separate clonings of VGAT and GAD 65 ͞ GAD 67 suggest that these are distinct proteins encoded by different genes (1, 16). VGAT is an integral membrane protein with 10 transmembrane domains (16), whereas GAD 65 and GAD 67 are soluble proteins lacking any transmembrane regions (1). Hence, it is clear that two separate protein entities are responsible for synthesis and packaging of GABA into SVs. Recently, we have shown that GAD 65 may become anchored to SVs through protein complex formation first with HSC70, followed by interaction with CSP, an intrinsic SV protein (15). In this article, we have shown the presence of HSC70 and CSP in purified GABAergic SV (Fig. 5 d ). In addition, we provide evidence to show that the protein complex includes two additional SV proteins, namely, VGAT and CaMKII (Fig. 5 a–c ). Furthermore, we have used purified GABAergic-specific SVs to demonstrate that [ 3 H]GABA, newly synthesized from [ 3 H]Glu by SV-associated GAD, is taken up preferentially into SV over the preexisting cytosolic GABA (Fig. 4 a ). The material accumulated inside SVs has also been posi- tively identified as GABA (Fig. 4 b ). Based on these observations, we proposed that there is a structural and functional coupling between the synthesis and packaging of GABA into SV. This hypothesis is further supported by the following lines of evidence. First, the newly synthesized [ 3 H]GABA from [ 3 H]Glu by SV-associated GAD is taken up efficiently by VGAT. The VGAT activity is markedly inhibited when the GAD inhibitor, hydrazine or aminooxyacetate, is included in the reaction system, suggesting a functional coupling between MGAD and VGAT. Second, although GAD is a soluble protein, it can anchor to SV through its interaction with HSC70 and several members of SV proteins including CSP, CaMKII, and VGAT (Fig. 5 and ref. 15). This protein machinery provides a structural basis for an effi- cient coupling between GABA synthesis by GAD and GABA packaging into SV by VGAT. Third, a good correlation between the expression of VGAT and GAD 65 in various brain regions as well as at various developmental stages (data not shown) is compatible with the above hypothesis. Fourth, in addition to the GABA system, we have found that a similar mechanism may also be involved in the dopaminergic systems.** Recently, we re- ported that the membrane-associated tyrosine hydroxylase, the rate-limiting enzyme involved in dopaminergic synthesis, is activated by ATP through protein phosphorylation and inacti- vated by protein dephosphorylation. Furthermore, the activation of tyrosine hydroxylase mediated by ATP is abolished under conditions disrupting the proton gradient on the SV. Because the uptake of dopaminergic into SVs also depends on the proton gradient of the SV, these observations also support a coupling mechanism between dopaminergic synthesis and packaging into SV. In conclusion, we propose that GAD 65 is anchored to SVs by forming a protein complex first with HSC70, followed by the association with proteins on SVs, e.g., CSP, VGAT, and CaMKII. This protein complex functions as a machine to ensure that GABA biosynthesis and packaging into the SV is efficiently coupled. A model that depicts a functional and structural coupling of GABA synthesis, regulation, and packaging into SVs is proposed (Fig. 6). The physiological events leading from neuronal stimulation to activation of SV-associated GAD and subsequent packaging of GABA into the SV can be described as follows. GABA is released by exocytosis after the arrival of an action potential (stage 1). The SV is recycled by means of clathrin-coated pits (stage 2). The clathrin coat is then dissoci- ated from the vesicles through interaction with HSC70 (27). Vesicles are then returned to the resting state of SVs, where the proton gradient is restored by V-ATPase (stage 3). GAD 65 is activated through protein phosphorylation by a proton gradient- dependent protein kinase (stage 4). One of the candidates of protein kinase is CaMKII. GABA newly synthesized by GAD 65 is then transported into SVs by VGAT (stage 5). These refilled GABA-containing SVs are ready to be released upon arrival of a new action potential (stage 6). Previously, we reported that SGAD is activated by calcineurin-mediated dephosphorylation and inhibited by protein kinase A-mediated protein phosphor- ylation (22, 23). Here, we propose that when GABA neurons are stimulated, the influx of Ca 2 ϩ into the terminal results in dephosphorylation and activation of SGAD ͞ GAD 67 (stage 7). GABA synthesized by SGAD ͞ GAD 67 in the cytosol may also be transported into SVs, although it represents a minor pathway (stage 8). Cytosolic GABA may also be metabolized to generate ATP through the GABA shunt pathway, which may be used to maintain electrochemical proton gradient for GABA transport (stage 9). The model proposed here could explain the efficiency of vesicular transport of GABA newly synthesized by SV- associated GAD 65 , but not GABA in the cytosolic pool. One can imagine that the active site of VGAT and the catalytic site of GAD 65 are tightly coupled in a key and lock manner. This tight structural coupling would allow an efficient transfer of GABA from its site of synthesis to the site of transport. It also prevents the access of GABA in the cytosol to reach the active site of VGAT, resulting in the minimum rate of transport of cytosolic GABA. However, in the absence of GAD 65 , the active site of VGAT will become available to cytosolic GABA, and vesicular transport of GABA can be restored to a certain extent. This proposed mechanism can explain the observation that GAD 65 knockout mice can survive and grow relatively normal, except with signs of deficiencies in GABA transmission such as increase in seizure susceptibility (28), absence of long-term depression (29), increase in anxiety-like behavior (30, 31), and lack of cortical plasticity (32). However, GAD 67 knockout is lethal. GAD 67 -deficient mice did not survive after birth because of cleft palate (28, 33). These observations are compatible with the notion that GAD 65 is primarily responsible for synthesis of GABA to be used as a neurotransmitter, whereas GAD 67 is responsible for GABA to be used for other functions such as serving as a signaling molecule in development, a source of energy, and a source of GABA released via nonvesicular mech- anism. Further studies on the 3D structure of GAD and its protein complex are needed to elucidate the molecular mecha- nism of coupling between GABA synthesis and its packaging into ...

Citations

... The degradation of tryptophan to 5-HTP to serotonin consumption forms the 5-HIAA, and the 5-hydroxy in the excretion process, if interdependence of chemical reactions with tryptophan synthesis were to be intruded, the postsynaptic etiology may be formed [6]. Since GABAA receptor is a ligand-gated chloride channel that mediates fast inhibitory signals through rapid postsynaptic membrane hyperpolarization, its forces in macroenvironment changes for cytoplasm directions are not negligible, such as the influences to the second round of presynaptic vesicles in the separation of glutamate and GABA by an anion exchange column [8, 14,22]. ...
Article
Full-text available
Background: Motivated by the questions in the neurological mechanisms of post-traumatic stress disorder (PTSD), the review studies into the details of hypothalamic-pituitary-adrenal (HPA) axis. The review is supplementary to the phenomenon that COVID-19 also triggers negative psychological symptoms and suicidality. Methods: The review takes γ-aminobutyric acid (GABA) beta receptors for conceptual framework in the transdisci-plinary literature search. Results: Evidence suggests, although interdependent, the presynaptic and postsynaptic elements of GABA activities are independent from each other in normative conditions. Conclusions: I take my series of clinical trials conducted for the past 2 to 3 years for the guidance of case presentation on the interpretations of the information gathered, and there is no obvious evidence that autism spectrum disorder is associated with the GABA irregularities in PTSD and COVID-19 infections. The presynaptic interventions' slight influence to the metabolites related to GABA synthesis and degradation suggests the interrelations between GABA synapses and immune reflex.
... GAD65 is expressed in the presynaptic end of nerve terminals in its inactive form and is converted to its active form at the post-natal stage to rapidly synthesize GABA for synaptic transmission (110). GAD65 is also responsible for packaging GABA after its synthesis (111). Additionally, GAD67 is expressed in the cell body and dendrites and is responsible for synthesizing basal levels of GABA (100). ...
... GABA binds GABAA and GABAB receptors to mediate the hyperpolarization of postsynaptic neurons, comprising an inhibitory signal (124, 125). The GAD Ab inhibits GAD65 to block GABA synthesis, thereby reducing the uptake of newly synthesized GABA in synaptic vesicles and its synaptic release (111,(126)(127)(128). ...
Article
Full-text available
Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities.
... However, puncta on PNN-bearing cells were significantly more intensely labeled, suggesting increased capacity for packaging of GABA and glutamate, respectively. Thus, these connections may be more efficient, favoring fewer, mature puncta over more numerous, but less established puncta [41,42]. These effects were more robust in vGAT than vGLUT, a change made evident by the decreased vGAT/vGLUT ratio in PV cells with PNNs (Fig. 4K). ...
Article
Full-text available
Psychological loss is a common experience that erodes well-being and negatively impacts quality of life. The molecular underpinnings of loss are poorly understood. Here, we investigate the mechanisms of loss using an environmental enrichment removal (ER) paradigm in male rats. The basolateral amygdala (BLA) was identified as a region of interest, demonstrating differential Fos responsivity to ER and having an established role in stress processing and adaptation. A comprehensive multi-omics investigation of the BLA, spanning multiple cohorts, platforms, and analyses, revealed alterations in microglia and the extracellular matrix (ECM). Follow-up studies indicated that ER decreased microglia size, complexity, and phagocytosis, suggesting reduced immune surveillance. Loss also substantially increased ECM coverage, specifically targeting perineuronal nets surrounding parvalbumin interneurons, suggesting decreased plasticity and increased inhibition within the BLA following loss. Behavioral analyses suggest that these molecular effects are linked to impaired BLA salience evaluation, leading to a mismatch between stimulus and reaction intensity. These loss-like behaviors could be rescued by depleting BLA ECM during the removal period, helping us understand the mechanisms underlying loss and revealing novel molecular targets to ameliorate its impact.
... Currently, there is no consensus as to whether anti-GAD antibodies cause disease directly or indirectly through cellular immunity. GAD65 is primarily expressed in the pre-synaptic end of GABAergic nerve terminals and can form a protein complex to anchor on the synaptic vesicle membrane [23]. When synaptic vesicles fuse with the plasma membrane, the epitopes of GAD65 can be temporarily exposed to antibodies [24]. ...
Article
Full-text available
Glutamic acid decarboxylase (GAD) antibody-related encephalitis is an autoimmune disease associated with intracellular neuronal antigens. We report on a rare case of GAD antibody-associated encephalitis complicated with focal segmental stiffness-person syndrome (SPS) in a middle-aged woman. The disease course lasted for >10 years, initially presenting with drug-resistant epilepsy, followed by stiffness of the right lower limb, and right upper limb involvement. The patient experienced anxiety and depression symptoms due to long-term illness. During hospitalization, serum and cerebrospinal fluid GAD antibodies were positive and no tumor was found. The symptoms were significantly relieved after corticosteroid therapy and intravenous immunoglobulin immunomodulation therapy. To the best of our knowledge, this case is the first to discuss the early recognition and treatment of chronic epilepsy and focal segmental SPS caused by anti-GAD antibody-related encephalitis.
... Moreover, we also found a significant increase in the GAD65 enzyme, but not GAD67 or GAT-1 (GABA Transporter-1) in the same region [92]. GAD65 is chiefly localized in the axon terminals [93], with increased GABA synthesis during intense synaptic activity mediated by this enzyme [94]. These findings substantiate the inference that there may be an extracellular increase in GABA in the epileptic primary SoCx. ...
Article
Full-text available
Absence seizures are hyperexcitations within the cortico-thalamocortical (CTC) network, however the underlying causative mechanisms at the cellular and molecular level are still being elucidated and appear to be multifactorial. Dysfunctional feed-forward inhibition (FFI) is implicated as one cause of absence seizures. Previously, we reported altered excitation onto parvalbumin-positive (PV+) interneurons in the CTC network of the stargazer mouse model of absence epilepsy. In addition, downstream changes in GABAergic neurotransmission have also been identified in this model. Our current study assessed whether dysfunctional FFI affects GABAA receptor (GABAAR) subunit expression in the stargazer primary somatosensory cortex (SoCx). Global tissue expression of GABAAR subunits α1, α3, α4, α5, β2, β3, γ2 and δ were assessed using Western blotting (WB), while biochemically isolated subcellular fractions were assessed for the α and δ subunits. We found significant reductions in tissue and synaptic expression of GABAAR α1, 18% and 12.2%, respectively. However, immunogold-cytochemistry electron microscopy (ICC-EM), conducted to assess GABAAR α1 specifically at synapses between PV+ interneurons and their targets, showed no significant difference. These data demonstrate a loss of phasic GABAAR α1, indicating altered GABAergic inhibition which, coupled with dysfunctional FFI, could be one mechanism contributing to the generation or maintenance of absence seizures.
... While GABA itself is predominantly cytosolic in beta cells, the GABA-synthesizing enzyme GAD65 localizes to strongly punctate cytoplasmic structures (51), previously described to be synaptic-like microvesicles (55,63). Because the concentration of GABA in the lumen of most GAD65 + puncta or insulin granules appears no different than that in the cytosol, these GAD65 + puncta seen in beta cells are unlikely to be synaptic-like microvesicles for GABA secretion. ...
Article
Full-text available
Gamma aminobutyric acid (GABA) is a non-proteinogenic amino acid and neurotransmitter that is produced in the islet at levels as high as in the brain. GABA is synthesized by the enzyme glutamic acid decarboxylase (GAD), of which the 65 kDa isoform (GAD65) is a major autoantigen in type 1 diabetes. Originally described to be released via synaptic-like microvesicles or from insulin secretory vesicles, beta cells are now understood to release substantial quantities of GABA directly from the cytosol via volume-regulated anion channels (VRAC). Once released, GABA influences the activity of multiple islet cell types through ionotropic GABAA receptors and metabotropic GABAB receptors. GABA also interfaces with cellular metabolism and ATP production via the GABA shunt pathway. Beta cells become depleted of GABA in type 1 diabetes (in remaining beta cells) and type 2 diabetes, suggesting that loss or reduction of islet GABA correlates with diabetes pathogenesis and may contribute to dysfunction of alpha, beta, and delta cells in diabetic individuals. While the function of GABA in the nervous system is wellunderstood, the description of the islet GABA system is clouded by differing reports describing multiple secretion pathways and effector functions. This review will discuss and attempt to unify the major experimental results from over 40 years of literature characterizing the role of GABA in the islet.
... However, the puncta that were present on PNN-bearing cells were significantly more intensely labeled, suggesting increased capacity for packaging of GABA and glutamate, respectively. Thus, these connections could be more efficient, favoring fewer, mature puncta over more numerous, but less developed puncta 36,37 . These effects were more robust in vGAT than vGLUT, a change made evident by the decreased vGAT/vGLUT ratio in PV cells with PNNs ( Figure 5G). ...
Preprint
Full-text available
Psychological loss is a common experience that erodes well-being and negatively impacts quality of life. The molecular underpinnings of loss are poorly understood, making it challenging to develop treatment strategies. Here, we investigate the mechanisms of loss using an enrichment removal (ER) paradigm in rats. A comprehensive multi-omics investigation of the basolateral amygdala (BLA), spanning multiple cohorts, platforms, and analyses, revealed alterations in microglia and extracellular matrix (ECM). Follow-up studies indicated that ER decreased microglia size, complexity, and phagocytosis, suggesting reduced immune surveillance. Loss also substantially increased ECM coverage, specifically targeting perineuronal nets surrounding parvalbumin interneurons, suggesting decreased plasticity and increased inhibition in the BLA. Behavioral analyses suggests that these molecular effects are linked to impaired BLA salience evaluation and flexibility, phenotypes that resemble emotional blunting observed in human loss. Taken together, these experiments help us understand the mechanisms underlying loss and reveal novel molecular targets to ameliorate its impact.
... Based on these reporters, we can conclude that most of the cytosolic content of dopaminergic axons is present in the synaptosome fraction (SYN) and available for discrimination by the fluorescence-activated synaptosome sorting (FASS) 21,27 procedure (Fig. 1a). Of note, a small fraction of Th seems associated with light membranes of the crude synaptic vesicle fraction, an observation reminiscent of the one made with GABA synthesizing enzymes 28 . ...
Article
Full-text available
Dopamine transmission is involved in reward processing and motor control, and its impairment plays a central role in numerous neurological disorders. Despite its strong pathophysiological relevance, the molecular and structural organization of the dopaminergic synapse remains to be established. Here, we used targeted labelling and fluorescence activated sorting to purify striatal dopaminergic synaptosomes. We provide the proteome of dopaminergic synapses with 57 proteins specifically enriched. Beyond canonical markers of dopamine neurotransmission such as dopamine biosynthetic enzymes and cognate receptors, we validated 6 proteins not previously described as enriched. Moreover, our data reveal the adhesion of dopaminergic synapses to glutamatergic, GABAergic or cholinergic synapses in structures we named “dopamine hub synapses”. At glutamatergic synapses, pre- and postsynaptic markers are significantly increased upon association with dopamine synapses. Dopamine hub synapses may thus support local dopaminergic signalling, complementing volume transmission thought to be the major mechanism by which monoamines modulate network activity. The neurotransmitter dopamine is an important regulator of brain function. Here the authors describe “dopamine hub synapses”, where dopamine transmission may act in synergy with other neurotransmitters.
... GAD67 has been found to be constitutively active and provide the majority of the cytosolic GABA, while GAD65 is mainly responsible for synaptic GABA production released from synaptic vesicles during neurotransmission (Pinal and Tobin, 1998;Battaglioli et al., 2003). Together, both isoforms exhibit different cellular distribution and structural properties (Dupuy and Houser, 1996;Jin et al., 2003). Their function strongly depends on post-translational modifications including phosphorylation, palmitoylation, and cleavage (Lee et al., 2019). ...
Article
Full-text available
Adaptive plasticity processes are required involving neurons as well as non-neuronal cells to recover lost brain functions after an ischemic stroke. Recent studies show that gamma-Aminobutyric acid (GABA) has profound effects on glial and immune cell functions in addition to its inhibitory actions on neuronal circuits in the post-ischemic brain. Here, we provide an overview of how GABAergic neurotransmission changes during the first weeks after stroke and how GABA affects functions of astroglial and microglial cells as well as peripheral immune cell populations accumulating in the ischemic territory and brain regions remote to the lesion. Moreover, we will summarize recent studies providing data on the immunomodulatory actions of GABA of relevance for stroke recovery. Interestingly, the activation of GABA receptors on immune cells exerts a downregulation of detrimental anti-inflammatory cascades. Conversely, we will discuss studies addressing how specific inflammatory cascades affect GABAergic neurotransmission on the level of GABA receptor composition, GABA synthesis, and release. In particular, the chemokines CXCR4 and CX3CR1 pathways have been demonstrated to modulate receptor composition and synthesis. Together, the actual view on the interactions between GABAergic neurotransmission and inflammatory cascades points towards a specific crosstalk in the post-ischemic brain. Similar to what has been shown in experimental models, specific therapeutic modulation of GABAergic neurotransmission and inflammatory pathways may synergistically promote neuronal plasticity to enhance stroke recovery.
... That leaves us to explore how GAD65, an intracellular enzyme found in beta cells, might get recognized by bacterial-derived anti-GAD T cells. Pre-clinical studies demonstrated that GAD65 could associate with the plasma membrane and enter the extracellular space [26,27]. In this scenario, "deputized" beta cells that present GAD65 might have an opportunity to interact with GAD sensitized T cells [28,29]. ...
Article
Full-text available
A variety of islet autoantibodies (AAbs) can predict and possibly dictate eventual type 1 diabetes (T1D) diagnosis. Upwards of 75% of those with T1D are positive for AAbs against glutamic acid decarboxylase (GAD65 or GAD), a producer of gamma-aminobutyric acid (GABA) in human pancreatic beta cells. Interestingly, bacterial populations within the human gut also express GAD and produce GABA. Evidence suggests that dysbiosis of the microbiome may correlate with T1D pathogenesis and physiology. Therefore, autoimmune linkages between the gut microbiome and islets susceptible to autoimmune attack need to be further elucidated. Utilizing in silico analyses, we show that 25 GAD sequences from human gut bacterial sources show sequence and motif similarities to human beta cell GAD65. Our motif analyses determined that most gut GAD sequences contain the pyroxical dependent decarboxylase (PDD) domain of human GAD65, which is important for its enzymatic activity. Additionally, we showed overlap with known human GAD65 T cell receptor epitopes, which may implicate the immune destruction of beta cells. Thus, we propose a physiological hypothesis in which changes in the gut microbiome in those with T1D result in a release of bacterial GAD, thus causing miseducation of the host immune system. Due to the notable similarities we found between human and bacterial GAD, these deputized immune cells may then target human beta cells leading to the development of T1D.